A Step Forward for Long-Acting PCSK9 Inhibition Improvements Without a Breakthrough

被引：1
|
作者：
Santos, Raul D. [1 ,2 ]
Nasir, Khurram [3 ]
Shapiro, Michael D. [4 ]
机构：
[1] Univ Sao Paulo, Hosp Israelita Albert Einstein, Acad Res Org, Sao Paulo, Brazil
[2] Univ Sao Paulo, Heart Inst InCor, Sao Paulo, Brazil
[3] Houston Methodist DeBakey Heart & Vasc Ctr, Dept Cardiol, Div Cardiovasc Prevent & Wellness, Houston, TX USA
[4] Wake Forest Univ, Bowman Gray Sch Med, Ctr Prevent Cardiovasc Dis, Sect Cardiovasc Med, Winston Salem, NC 27157 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2024年 / 84卷 / 20期
基金：
美国国家卫生研究院;
关键词：
KEY WORDS LDL-C; lipoproteins; mixed hyperlipemia; nonfamilial hypercholesterolemia; PCSK9; recaticimab;
D O I：
10.1016/j.jacc.2024.09.019
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2048 / 2050
页数：3
相关论文
共 50 条
  • [31] Predicting the benefits and risks of PCSK9 inhibition
    David Holmes
    Nature Reviews Endocrinology, 2017, 13 : 65 - 65
  • [32] PCSK9 inhibition and inflammation: A narrative review
    Ruscica, Massimiliano
    Tokgozoglu, Lale
    Corsini, Alberto
    Sirtori, Cesare R.
    ATHEROSCLEROSIS, 2019, 288 : 146 - 155
  • [33] PCSK9 inhibition in the management of familial hypercholesterolemia
    Ogura, Masatsune
    JOURNAL OF CARDIOLOGY, 2018, 71 (1-2) : 1 - 7
  • [34] Lipoprotein(a) and PCSK9 inhibition: clinical evidence
    Ruscica, Massimiliano
    Greco, Maria Francesca
    Ferri, Nicola
    Corsini, Alberto
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0L) : L53 - L56
  • [35] Lipoprotein (a), arterial inflammation, and PCSK9 inhibition
    Tardif, Jean-Claude
    Rheaume, Eric
    Rhainds, David
    Dube, Marie-Pierre
    EUROPEAN HEART JOURNAL, 2019, 40 (33) : 2782 - 2784
  • [36] PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
    Tavori, Hagai
    Giunzioni, Ilaria
    Fazio, Sergio
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2015, 22 (02) : 126 - 132
  • [37] PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
    Delialis, Dimitrios
    Dimopoulou, Maria-Angeliki
    Papaioannou, Maria
    Kotsira, Georgia
    Maneta, Eleni
    Mavraganis, Georgios
    Loutos, Christos
    Georgiopoulos, Georgios
    Stamatelopoulos, Kimon
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (23) : 1802 - 1824
  • [38] PCSK9 inhibition and the global diabetes epidemic
    Luca Mascitelli
    Mark R. Goldstein
    Diabetologia, 2017, 60 : 751 - 752
  • [39] Genetic Inhibition of PCSK9 and Liver Function
    Rimbert, Antoine
    Smati, Sarra
    Dijk, Wieneke
    Le May, Cedric
    Cariou, Bertrand
    JAMA CARDIOLOGY, 2021, 6 (03) : 353 - 354
  • [40] PCSK9 inhibition for autosomal recessive hypercholesterolemia
    Chemello, Kevin
    Martin, Cesar
    Lambert, Gilles
    ATHEROSCLEROSIS, 2019, 284 : 209 - 211
12345